UPDATED: Solid Bio’s long, troubled slog through the clinic yields 'encouraging' early data and no new safety concerns. It's not winning over investors yet
Those who have been following the gene therapy space would be familiar with Solid Bio’s IGNITE-DMD trial. Beset with safety issues, the Phase I/II study was held down by clinical holds for the better part of the last three years, while the Duchenne-focused biotech watched bigger rivals dash by toward pivotal work.
There was just one thing that we’ve never seen: data from the study on how patients are doing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.